Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2021 Mar 8;3(3):CD003427.
doi: 10.1002/14651858.CD003427.pub5.

Prophylactic antibiotics for preventing pneumococcal infection in children with sickle cell disease

Angela E Rankine-Mullings  1 , Shirley Owusu-Ofori  2
Affiliations
Meta-Analysis

Prophylactic antibiotics for preventing pneumococcal infection in children with sickle cell disease

Angela E Rankine-Mullings et al. Cochrane Database Syst Rev. .

Abstract

Background: Sickle cell disease (SCD) is a group of inherited disorders that result in haemoglobin abnormalities and other complications. Injury to the spleen, among other factors, contribute to persons with SCD being particularly susceptible to infection. Infants and very young children are especially vulnerable. The 'Co-operative Study of Sickle Cell Disease' observed an incidence rate for pneumococcal septicaemia of 10 per 100 person-years in children under the age of three years. Vaccines, including customary pneumococcal vaccines, may be of limited use in this age group. Therefore, prophylactic penicillin regimens may be advisable for this population. This is an update of a Cochrane Review which was first published in 2002, and previously updated, most recently in 2017. OBJECTIVES: To compare the effects of antibiotic prophylaxis against pneumococcus in children with SCD receiving antibiotic prophylaxis compared to those without in relation to: 1. incidence of Streptococcus pneumoniae infection; 2. mortality (as reported in the included studies); 3. drug-related adverse events (as reported in the included studies) to the individual and the community; 4. the impact of discontinuing at various ages on incidence of infection and mortality.

Search methods: We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Haemoglobinopathies Trials Register, which is comprised of references identified from comprehensive electronic database searches and also two clinical trials registries: ClinicalTrials.gov and the WHO International Registry Platform (not in 2020 given access issues relating to Covid-19 pandemic). Additionally, we carried out hand searching of relevant journals and abstract books of conference proceedings. Date of the most recent search: 25 January 2021.

Selection criteria: All randomised or quasi-randomised controlled trials comparing prophylactic antibiotics to prevent pneumococcal infection in children with SCD with placebo, no treatment or a comparator drug.

Data collection and analysis: The standard methodological procedures expected by Cochrane were used. Both authors independently extracted data and assessed trial quality. The authors used the GRADE criteria to assess the certainty of the evidence.

Main results: Six trials were identified by the searches, of which three trials were eligible for inclusion. A total of 880 children, who were between three months to five years of age at randomization were included. The included studies were conducted in centres in the USA and in Kingston, Jamaica. In trials that investigated initiation of penicillin on risk of pneumococcal infection, the odds ratio was 0.37 (95% confidence interval 0.16 to 0.86) (two trials, 457 children) (low-certainty evidence), while for withdrawal the odds ratio was 0.49 (95% confidence interval 0.09 to 2.71) (one trial, 400 children) (low-certainty evidence). Adverse drug effects were rare and minor. Rates of pneumococcal infection were found to be relatively low in children over the age of five years. Overall, the certainty of the evidence for all outcomes was judged to be low. The results from the risk of bias assessment undertaken identified two domains in which the risk of bias was considered to be high, these were incomplete outcome data (attrition bias) (two trials) and allocation concealment (selection bias) (one trial). Domains considered to have a low risk of bias for all three trials were selective reporting (reporting bias) and blinding (performance and detection bias).

Authors' conclusions: The evidence examined was determined to be of low certainty and suggests that prophylactic penicillin significantly reduces risk of pneumococcal infection in children with homozygous SCD, and is associated with minimal adverse reactions. Further research may help to determine the ideal age to safely withdraw penicillin.

PubMed Disclaimer

Conflict of interest statement

Both authors: none known.

Figures

1
1
Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
2
2
Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
1.1
1.1. Analysis
Comparison 1: Penicillin prophylaxis versus standard care, Outcome 1: Incidence of pneumococcal infection (for initiation or withdrawal of treatment)
1.2
1.2. Analysis
Comparison 1: Penicillin prophylaxis versus standard care, Outcome 2: Incidence of pneumococcal infection (subgrouped by vaccination)
1.3
1.3. Analysis
Comparison 1: Penicillin prophylaxis versus standard care, Outcome 3: Deaths (for initiation or withdrawal of treatment)
1.4
1.4. Analysis
Comparison 1: Penicillin prophylaxis versus standard care, Outcome 4: Adverse drug effects
1.5
1.5. Analysis
Comparison 1: Penicillin prophylaxis versus standard care, Outcome 5: Requirement for other courses of antibiotics
See this image and copyright information in PMC

Update of

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

References to studies included in this review

John 1984 {published data only}
    1. John AB, Ramlal A, Jackson H, Maude GH, Sharma AW, Serjeant GR. Prevention of pneumococcal infection in children with homozygous sickle cell disease. British Medical Journal (Clinical Research Edition) 1984;288(6430):1567-70. - PMC - PubMed
PROPS 1986 {published data only}
    1. Gaston MH, Verter J. Sickle cell anaemia trial. Statistics in Medicine 1990;9(1-2):45-51. - PubMed
    1. Gaston MH, Verter JI, Woods G, Pegelow C, Kelleher J, Presbury G, et al. Prophylaxis with oral penicillin in children with sickle cell anemia: a randomized trial. New England Journal of Medicine 1986;314(25):1593-9. - PubMed
PROPS II 1995 {published data only}
    1. American Family Physician. Use of penicillin prophylaxis in sickle cell disease. American Family Physician 1996;53(5):1828-9. [CENTRAL: CN-01764080] [CFGD REGISTER: SC374] [EMBASE: 26119795]
    1. Bjornson AB, Falletta JM, Verter JI, Buchanan GR, Miller ST, Pegelow CH, et al. Serotype-specific immunoglobulin G antibody responses to pneumococcal vaccine in children with sickle cell anemia: effects of continued penicillin prophylaxis. Journal of Pediatrics 1996;129(6):828-35. [CFGD REGISTER: SC31c] - PubMed
    1. Falletta JM, Woods GM, Verter JI, Buchanan GR, Pegelow CH, Iyer RV, et al. Discontinuing penicillin prophylaxis in children with sickle cell anemia. Prophylactic Penicillin Study II. Journal of Pediatrics 1995;127(5):685-90. [CFGD REGISTER: SC31a] - PubMed
    1. Woods GM, Jorgensen JH, Waclawiw MA, Reid C, Wang W, Pegelow CH, et al. Influence of penicillin prophylaxis on antimicrobial resistance in nasopharyngeal S. pneumoniae among children with sickle cell anemia. The Ancillary Nasopharyngeal Culture Study of Prophylactic Penicillin Study II. Journal of Pediatric Hematology/Oncology 1997;19(4):327-33. [CFGD REGISTER: SC31b] - PubMed

References to studies excluded from this review

Babiker 1986 {published data only}
    1. Babiker MA. Prophylaxis of pneumococcal infection in sickle-cell disease by the combined use of vaccination and penicillin. Annals of Tropical Paediatrics 1986;6(3):179-81. [CENTRAL: CN-00045321] [CFGD REGISTER: SC375] [DOI: 10.1080/02724936] [PMID: ] - DOI - PubMed
Berkovitch 1998 {published data only}
    1. Berkovitch M, Papadouris D, Shaw D, Onuaha N, Dias C, Olivieri NF. Trying to improve compliance with prophylactic penicillin therapy in children with sickle cell disease. British Journal of Clinical Pharmacology 1998;45(6):605-7. - PMC - PubMed
Lewthwaite 1962 {published data only}
    1. Lewthwaite CJ. A trial of chemoprophylaxis in sickle cell anaemia. Preliminary communication.. East African Medical Journal 1962;39(5):196-9. - PubMed

Additional references

Anglin 1984
    1. Anglin DL, Siegel JD, Pacini DL, Smith SJ, Adams G, Buchanan G. Effect of penicillin prophylaxis on nasopharyngeal colonization with Streptococcus pneumoniae in children with sickle cell anemia. Journal of Pediatrics 1984;104(1):18-22. - PubMed
Bjornson 1996
    1. Bjornson AB, Falletta JM, Verter JI, Buchanan GR, Miller ST, Pegelow CH, et al. Serotype-specific immunoglobulin G antibody responses to pneumococcal vaccine in children with sickle cell anemia: effects of continued penicillin prophylaxis. Journal of Pediatrics 1996;129(6):828-35. [CFGD REGISTER: SC31c] - PubMed
BNF 2020
    1. Joint Formulary Committee. British National Formulary. 79 edition. London: BMJ Group and Pharmaceutical Press, 2020.
Bonten 2015
    1. Bonten MJM, Huijts SM, Bolkenbaas M, Webber C, Patterson S, Gault S, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. New England Journal of Medicine 2015;372(12):1114-25. - PubMed
Brousee 2014
    1. Brousse V, Makani J, Rees DC. Management of sickle cell disease in the community. BMJ 2014;348:g1765. [DOI: 10.1136/bmj.g1765] - DOI - PMC - PubMed
Bush 2016
    1. Bush K, Bradford PA. β-Lactams and β-Lactamase Inhibitors: An Overview. Cold Spring Harbour Perspectives in Medicine 2016;6(8):a025247. - PMC - PubMed
Cannas 2019
    1. Cannas G, Merazga S, Virot E. Sickle cell disease and infections in high- and low-income countries. Mediterranean Journal of Hematology and Infectious Diseases 2019;11(1):e2019042. [DOI: 10.4084/MJHID.2019.042] - DOI - PMC - PubMed
CDC 2019
    1. Centers for Disease Control and Prevention. https://www.cdc.gov/ncbddd/sicklecell/data.html. www.cdc.gov/ncbddd/sicklecell/data.html (accessed 18 November 2020).
Chesney 1992
    1. Chesney PJ. The escalating problem of antimicrobial resistance in Streptococcus pneumoniae. American Journal of Diseases of Children 1992;146(8):912-6. - PubMed
Conceição da Guarda 2020
    1. Conceição da Guarda C, Cocou Modeste Alexandre Yahouédéhou S, Pereira Santiago R, Felix de Lima Fernandes C, Santana dos Santos Neres J, Mateus de Jesus Oliveira A, et al. Investigation of Lipid Profile and Clinical Manifestations in SCA Children. Disease Markers 2020;2020:8842362. [DOI: 10.1155/2020/8842362] - DOI - PMC - PubMed
Craig 2000
    1. Craig WA. Pharmacokinetics of antibiotics with special emphasis on cephalosporins. Clinical Microbiology and Infection 2000;6 (Suppl 3):46-9. - PubMed
Cummins 1991
    1. Cummins D, Heuschkel R, Davies SC. Penicillin prophylaxis in children with sickle cell disease in Brent. BMJ 1991;302(6783):989-90. - PMC - PubMed
Davies 2004
    1. Davies GE, Hirst C, Lottenberg R, Dower N. Pneumococcal vaccines for sickle cell disease (Cochrane Review). Cochrane Database of Systematic Reviews 2004, Issue 1. Art. No: CD003885. [DOI: 10.1002/14651858.CD003885.pub2] - DOI - PMC - PubMed
Daw 1997
    1. Daw NC, Wilimas JA, Wang WC, Presbury GJ, Joyner RE, Harris SC, et al. Nasopharyngeal carriage of penicillin resistant Streptococcus Pneumoniae in children with sickle cell disease. Pediatrics 1997;99(4):E7. - PubMed
Desselas 2020
    1. Desselas E, Thuret I, Kaguelidou F, Benkerrou M, Montalembert M, Odièvre M-H, et al. Mortality in children with sickle cell disease in mainland France from 2000 to 2015. Haematologica 2020;105(9):e440-3. - PMC - PubMed
Di Liberto 2016
    1. Di Liberto G, Kiger L, Marden MC, Boyer L, Canoui Poitrine F, Conti M, et al. Dense red blood cell and oxygen desaturation in sickle-cell disease. American Journal of Hematology 2016;91(10):1008-13. [DOI: 10.1002/ajh.24467] - DOI - PubMed
Dormandy 2018
    1. Dormandy E, James J, Inusa B, Rees D. How many people have sickle cell disease in the UK? Journal of Public Health 2018;40(3):e291-5. [DOI: 10.1038/nrdp.2018.10] - DOI - PubMed
Ginsburg 1982
    1. Ginsburg CM, McCracken GH, Zweighaft TC. Serum penicillin concentrations after intramuscular administration of benzathine penicillin G in children. Pediatrics 1982;69(4):452-4. - PubMed
Higgins 2003
    1. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60. - PMC - PubMed
Higgins 2011
    1. Higgins 2011: Higgins JPT, Altman DG, Sterne JAC, editor (s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Kato 2018
    1. Kato GJ, Piel FB, Reid CD, Gaston MH, Ohene-Frempong K, Krishnamurti L, et al. Sickle cell disease. Nature Reviews. Disease Primers 2018;4:18010. [DOI: 10.1038/nrdp.2018.10] - DOI - PubMed
King 2011
    1. King L, Ali S, Knight-Madden J, MooSang M, Reid M. Compliance with intramuscular penicillin prophylaxis in children with sickle cell disease in Jamaica. West Indian Medical Journal 2011;60(2):177-80. [PMID: ] - PubMed
Lees 2000
    1. Lees CM, Davies S, Dezateux C. Neonatal screening for sickle cell disease (Cochrane Review). Cochrane Database of Systematic Reviews 2000, Issue 1. Art. No: CD001913. [DOI: 10.1002/14651858.CD001913] - DOI - PMC - PubMed
Leikin 1989
    1. Leikin SL, Gallagher D, Kinney TR, Sloane D, Klug P, Rida W. Mortality in children and adolescents with sickle cell disease. Co-operative Study of Sickle Cell Disease. Pediatrics 1989;84(3):500-8. - PubMed
Lobel 1982
    1. Lobel JS, Bove KE. Clinicopathologic characteristics of septicaemia in sickle cell disease. American Journal of Diseases of Children 1982;136(6):543-7. - PubMed
McCavit 2011
    1. McCavit TL, Quinn CT, Techasaensiri C, Rogers ZR. Increase in invasive Streptococcus pneumoniae infections in children with sickle cell disease since pneumococcal conjugate vaccine licensure. Journal of Pediatrics 2011;158(3):505-7. - PMC - PubMed
Nunes 2012
    1. Nunes MC, Madhi SA. Safety, immunogenicity and efficacy of pneumococcal conjugate vaccine in HIV-infected individuals. Human Vaccines & Immunotherapeutics 2012;8(2):161-73. - PMC - PubMed
Oligbu 2018
    1. Oligbu G, Collins S, Sheppard C, Fry N, Dick M, Streetly A, et al. Risk of Invasive Pneumococcal Disease in Children with Sickle Cell Disease in England: A National Observational Cohort Study, 2010–2015. Archives of Disease in Childhood 2018;103(7):643-7. - PubMed
Oligbu 2019
    1. Oligbu G, Fallaha M, Pay L, Ladhani S. Risk of invasive pneumococcal disease in children with sickle cell disease in the era of conjugate vaccines: a systematic review of the literature. British Journal of Haematology 2019;185(4):743-51. - PubMed
Pai 2000
    1. Pai VB, Nahata MC. Duration of penicillin prophylaxis in sickle cell anemia: issues and controversies. Pharmacotherapy 2000;20(1):110-7. - PubMed
Platt 1994
    1. Platt OS, Brambilla DJ, Rosse WF, Milner PF, Castro O, Steinberg MH, et al. Mortality in sickle cell disease: life expectancy and risk factors for early death. New England Journal of Medicine 1994;330(23):1639-44. - PubMed
Quinn 2016
    1. Quinn CT. Minireview: Clinical severity in sickle cell disease: the challenges of definition and prognostication. Experimental Biology and Medicine 2016;241(7):679–88. [DOI: 10.1177/1535370216640385] - DOI - PMC - PubMed
RevMan 2020 [Computer program]
    1. The Cochrane Collaboration Review Manager (RevMan). Version 5.4. The Cochrane Collaboration, 2020.
Robinson 1966
    1. Robinson MG, Watson RJ. Pneumococcal meningitis in sickle-cell anemia. The New England Journal of Medicine 1966;274(18):1006-8. - PubMed
Saraf 2014
    1. Saraf S, Molokie RE, Nouraie M, Sable CA, Luchtman-Jones L, Ensing GJ, et al. Differences in the clinical and genotypic presentation of sickle cell disease around the world. Paediatric Respiratory Reviews 2014;15(1):4-12. [DOI: 10.1016/j.prrv.2013.11.003] - DOI - PMC - PubMed
Serjeant 2001
    1. Serjeant GR, Serjeant BE. The immune system. In: Sickle Cell Disease. 3rd edition. Oxford University Press, 2001:153-66.
Sterne 2011
    1. Sterne JA, Egger M, Moher D. Chapter 10: Addressing reporting biases. In: Higgins JP, Green S (editors). Cochrane Handbook forSystematic Reviews of Interventions Version 5.1 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
Teach 1998
    1. Teach SJ, Lillis KA, Grossi M. Compliance with penicillin prophylaxis in patients with sickle cell disease. Archives of Pediatrics & Adolescent Medicine 1998;152(3):274-8. [DOI: 10.1001/archpedi.152.3.274] - DOI - PubMed
Ware 2017
    1. Ware RE, de Montalembert M, Tshilolo L, Abboud MR. Sickle cell disease [Lancet]. Lancet 2017;390(10091):311-32. [DOI: 10.1016/S0140-6736(17)30193-9] - DOI - PubMed
Woods 1997
    1. Woods GM, Jorgensen JH, Waclawiw MA, Reid C, Wang W, Pegelow CH, et al. Influence of penicillin prophylaxis on antimicrobial resistance in nasopharyngeal S. pneumoniae among children with sickle cell anemia. The Ancillary Nasopharyngeal Culture Study of Prophylactic Penicillin Study II. Journal of Pediatric Hematology/Oncology 1997;19(4):327-33. - PubMed
Wyber 2013
    1. Wyber R, Taubert K, Marko S, Kaplan E. Benzathine Penicillin G for the Management of RHD: Concerns About Quality and Access, and Opportunities for Intervention and Improvement. Global Heart 2013;8(3):227-34. - PubMed
Yawn 2014
    1. Yawn BP, Buchanan GR, Afenyi-Annan AN, Ballas SK, Hassell KL, James AH, et al. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. JAMA 2014;312(10):1033-48. [DOI: 10.1001/jama.2014.10517] - DOI - PubMed
Zarkowsky 1986
    1. Zarkowsky HS, Gallagher D, Gill FM, Wang WC, Falletta JM, Lande WM, et al. Bacteremia in sickle hemoglobinopathies. Journal of Pediatrics 1986;109(4):579-85. - PubMed

References to other published versions of this review

Hirst 2002
    1. Hirst C, Owusu-Ofori S. Prophylactic antibiotics for preventing pneumococcal infection in children with sickle cell disease. Cochrane Database of Systematic Reviews 2002, Issue 3. Art. No: CD003427. [DOI: 10.1002/14651858.CD003427] - DOI - PubMed
Hirst 2012
    1. Hirst C, Owusu-Ofori S. Prophylactic antibiotics for preventing pneumococcal infection in children with sickle cell disease. Cochrane Database of Systematic Reviews 2012, Issue 9. Art. No: CD003427. [DOI: 10.1002/14651858.CD003427.pub2] - DOI - PubMed
Rankine‐Mullings 2017
    1. Rankine‐Mullings AE, Owusu‐Ofori S. Prophylactic antibiotics for preventing pneumococcal infection in children with sickle cell disease. Cochrane Database of Systematic Reviews 2017, Issue 10. Art. No: CD003427. [DOI: 10.1002/14651858.CD003427.pub4] - DOI - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources